冠心病患者冠脉搭桥术前后血浆可溶性Fas蛋白的表达

Expression of plasma sFas in CAD patients during perioperative period of CABG

目的研究冠心病患者冠脉搭桥术前后血浆细胞凋亡抑制物sFas的表达及临床意义。方法应用酶联免疫吸附双抗体夹心法(ELISA),分别测定了31例冠心病(CAD)患者冠脉搭桥术术前及术后不同时间点和20例非CAD患者的血浆sFas的水平。结果CAD患者术前血浆sFas水平明显高于对照组(P<0.05),其中不稳定型心绞痛组明显高于稳定型心绞痛组(P<0.01),CAD患者冠脉搭桥术后血浆sFas水平发生变化,于2周后降至正常水平。结论这些数据首次表明sFas是一种区别稳定型及不稳定型心绞痛的重要的血清学标志,提示Fas系统介导的细胞凋亡可能参与了CAD的发生发展过程。

Objective To study the expression and clinical significance of plasma soluble Fas, an inhibitor of apoptosis in CAD patients during perioperative period of CABG. Methods By specific enzyme-linked immunosorbent assay （ELISA） sFas was measured in the plasma from 31 CAD patients （14 stable angina and 17 unstable angina patients） and 20 subjects without CAD as controls. Results Plasma level of sFas was significantly increased in CAD patients as compared with controls（P〈0.05）, especially in unstable angina patients relative to stable angina ones（P〈0.01）. There were significant differences in plasma level of sFas in CAD patients during perioperative period of CABG. Conclusion These data provide the first evidence that sFas is an important serological markers that may help to discriminate between stable and unstable angina. The great changes of plasma sFas level in CAD patients during perioperative period of CABG indicate that Fas/Fas-L system induced apoptosis may play an important role in the development of CAD.